The long awaited all-oral therapy for hepatitis C virus infection has officially been inaugurated by the registration of the hepatitis C nucleotide inhibitor sofosbuvir in a combination regimen with ribavirin. More recently, the oral array to treat hepatitis C has been enriched by the arrival of the NS5A inhibitors ledipasvir (also in a single formulation with sofosbuvir, Harvoni ® ) and daclatasvir; the protease inhibitor simeprevir, and the Viekirax ® + Exviera TM regimen based on the ritonavir boosted protease inhibitor paritaprevir; the NS5A inhibitor ombitasvir, and the non-nucleoside inhibitor dasabuvir. Owing to the budget-breaking price of the newer oral medicines, the Italian National Health System elected to restrict reimbursement of oral anti-hepatitis C therapy to patients with advanced liver disease or transplanted organs, and those who are interferon unable, only. While this therapeutic strategy harmonizes with principles of distributive justice, at the same time it fuelled the argument of its doubtful cost-effectiveness, owing to the National Health System's reimbursement of the sole sofosbuvir + ribavirin regimen, which has suboptimal efficacy against the prevalent hepatitis C virus genotype 1b. As a consequence, we are left with a number of uncertainties regarding the optimal treatment modality for certain subgroups of hepatitis C patients, and the clinical benefits provided by hepatitis C virus clearance in patients with advanced liver disease.
Introduction
Owing to the regulatory approval of first and second wave of directly acting antiviral agents (DAAs) against hepatitis C, the most awaited golden era of interferon-free therapy for chronic hepatitis C has officially begun [1] [2] [3] [4] [5] [6] [7] [8] . With all the caveats imposed by money constraints, in a few years' time we expect such a therapeutic breakthrough to translate into substantial clinical benefits for the many patients who are chronically infected with the hepatitis C virus (HCV). Recently, a questionnaire based survey conducted in 63 Hepatology centres scattered throughout Italy and, in parallel, a review of the National Health System registries led to the identification of more than 350,000 such patients, mostly attending hospital-based Hepatology centres [9] . Included in this cohort are also 30,000 patients co-infected with the human immune deficiency virus (HIV) who are receiving care in specialized Infectious Disease centres, as well as at least 25,000 inmates and 70,000 individuals, including legal migrants, who are under the care of general practitioners and are not referred to tertiary care centres. These worrisome figures of HCV epidemiology notwithstanding, known hepatitis C carriers likely underrepresent the real burden of HCV disease in Italy, where at least one million chronically infected individuals are estimated to cluster in the aged strata of the general population [10] . Following the marketing of highly effective and safe, yet budget-breaking, oral regimens to treat HCV infection, questions have been raised on whether the currently endorsed lifesaving strategy of treating patients most in need of care will indeed succeed in reducing hepatitis C-related mortality in our population, and therefore be considered cost-effective. No question, in fact, that a more cost-effective strategy would be treatment all infected subjects with the aim of eradicating HCV in the community and preventing the accumulation of patients with advanced liver disease; yet this approach cannot be pursued due to money constrains [11] . Not surprisingly, therefore, along with other European countries, the National Health System (NHS) in Italy had to tone down its ambitious aims ultimately endorsing a lifesaving strategy of restricting anti-HCV treatment to groups of patients with more advanced liver disease and those who are interferon unable [12] . We all acknowledge, however, that such a pragmatic approach was biased by the suboptimal efficacy of the available sofosbuvir (SOF) plus ribavirin (RBV) regimen, which even combined with pegylated interferon (Peg IFN) or extended for 24 weeks as an all-oral regimen, did not reach a 90% success rate in all patient groups -now considered a "must have" of HCV care. While awaiting the clinical outcome of second-wave all-oral combinations, very recently approved for reimbursement, the following issues on several unresolved "hurdles" in anti-HCV therapy have arisen: how to optimize treatment of special groups? What clinical benefits can HCV clearance provide patients with advanced liver disease? How will patients with renal impairment comply with the nucleotide inhibitor SOF, given the renal excretion of its toxic 007 metabolite? How should surveillance be standardized in patients achieving a sustained virological response (SVR)? Finally, how could patient access to all-oral antiviral therapy be improved in the near future?
The upcoming scenario of hepatitis C therapy with second-wave DAAs in Italy
Currently, in Italy reimbursement by NHS has been established for SOF and for the second wave protease inhibitor simeprevir (SMV). In a few months, the NS5A inhibitors daclatasvir (DCV) and ledipasvir (LDV) co-formulated with SOF (Harvoni ® ), and the non-nucleotide inhibitor based regimen 3D from AbbVie (Viekirax ® + Exviera TM ), will be reimbursed by the NHS, as well (Table 1) . Currently, subgroups of hepatitis C patients who are eligible to receive NHS-funded all-oral therapy include Child Pugh A and B cirrhotics and patients with a hepatocellular carcinoma (HCC) not fulfilling the criteria for being listed to liver transplantation (LT), who have completely responded to limited hepatic resection or local tumour ablation. Likewise, treatment is reimbursed for the following groups: patients with post-LT recurrent hepatitis C and advanced graft fibrosis (Metavir ≥ F3 or with fibrosing cholestatic hepatitis); patients with chronic hepatitis and cryoglobulinemic syndrome or non-Hodgkin lymphoma; patients with chronic hepatitis C and advanced fibrosis (Metavir ≥ F3); patients with decompensated cirrhosis listed for LT with MELD < 25 or with HCC within Milan criteria and an expected time on the list of at least 2 months; and finally patients with any (non-liver) organ transplantation and chronic hepatitis C, with Metavir ≥ 2. 
Improving treatment of subgroups of patients with genotype 1, 3 and 4
It is widely acknowledged that the SOF + RBV combination has suboptimal therapeutic efficacy in subgroups of patients with hepatitis C genotype 1 and 3, particularly those with advanced fibrosis and those with a previous failure to interferon-based therapy [1, 2, 12] . In these populations, the SVR rates are substantially higher following treatment with a combination of SOF with other DAAs, as recently validated in field practice reports from the US, Canada and Germany (HCV Target), the US (TRIO) and France (Temporary Authorization of Use, ATU). In the HCV Target consortium, encompassing 38 academic and 15 community medical centres, SOF was given in association with RBV in less than 10% of the genotype 1 population on the assumption of unsatisfactory SVR rates and incremental cost of extended treatment to 24 weeks; the association of SOF + SMV was given for 12 or 24 weeks without RBV in 90% of patients, representing 2/3 of the overall cohort and resulting in satisfactory success rates. The SVR rates in fact were 85% in non-cirrhotics vs 79% in cirrhotics, and 92% in HCV-1b vs 84% in HCV-1a with a slight reduction of SVR rates (81%) in patients with a previous protease inhibitors failure [13] . By logistic regression analysis, low serum levels of albumin, HCV genotype 1a, previous clinical decompensation and failure to respond to triple therapy were associated with an increased risk of treatment failure. In the TRIO network of 31 academic and 119 community sites, treatment of genotype 1 patients with SOF + SMV was as successful as in the HCV Target, resulting in 10% higher rates of response compared to the association of SOF with Peg IFN + RBV [14] . Overall, the studies highlighted the remarkable rates of safety and effectiveness of the combination SOF + SMV where the need for RBV could be limited to patients infected by HCV genotype 1a and those with a previous failure to triple therapy. Surprisingly enough, the French study ATU reported unprecedented rates of therapeutic success for SOF + RBV combination therapy (87%) in a cohort enriched with cirrhotics and previous failures to triple therapy, largely exceeding the outcome of registration trials (Table 2a) . Overall, while field practice studies in the US validated the investigator-driven, proof-of-concept Cosmos study on SOF + SMV, the ATU study in France confirmed the safety and efficacy of the SOF + DCV combination in genotype 1 patients with advanced liver disease, which had been originally tested in a small proof-of-concept study of patients with less severe hepatitis C [15] . Further proof of the safety of all combo regimens were the negligible rates of discontinuation (approximately 6%) that were attributable to suboptimal adherence rather than to the few, mild to moderate adverse events recorded in patients with advanced liver disease. It should be noted, however, that outcomes of reallife practice with SOF combo regimens have been numerically overshadowed by the rates of therapeutic success in registration trials with SOF + LDV and Viekirax ® + Exviera TM , which combines a ritonavir-boosted protease inhibitor, a NS5A inhibitor and a nonnucleotide analogue polymerase inhibitor with and without RBV. The success rates of the latter regimen were particularly impressive in patients with compensated cirrhosis and severely impaired liver function, as well as with SOF + LDV in cirrhotics with decompensated liver disease and those who failed previous treatment with triple therapy with first generation DAAs [16] . Of note, in patients with decompensated liver disease and in treatment-experienced cirrhotics, a SOF + LDV regimen performed best in association with RBV (or without RBV if extended to 24 weeks); this was also the case for the Viekirax ® + Exviera TM regimen in genotype 1a cirrhotics and in those with a previous treatment failure. In the Italian scenario, where the combination of PegIFN + SOF + RBV has long been the strongest, yet suboptimal, option available to treat HCV genotype 1 with Metavir 3 and 4 fibrosis, a majority of these patients has been warehoused until the availability of more potent all-oral SOF combo regimens with DCV, SMV or LDV, or Viekirax ® + Exviera TM .
In our country, treatment of genotype 1 patients with decompensated cirrhosis remains a therapeutic hurdle, owing to the delayed approval of reimbursement of newer DAAs to combine with SOF, whereas SMV is the only available DAA in association with SOF, yet of uncertain safety in patients with advanced liver dysfunction. While in decompensated patients HCV suppression is lifesaving and stands as a prerequisite for improving the outcome of LT, the currently available standard of care SOF + RBV is poorly tolerated and offers limited chances of SVR even if extended to 48 weeks. This was clearly demonstrated in the US registration trial where 24 weeks of SOF + RBV led to HCV suppression in 93% of decompensated patients with reversal of ascites and encephalopathy in most, however without significant rates of HCV eradication [17] . HCV eradication was instead achieved in 90% of genotype 1 decompensated patients who received 12 weeks LDV + SOF + RBV, which resulted in an improvement of Child Pugh score in most patients [18] , an outcome conducive of improved prognosis also for those patients who are not listed for LT. While waiting for SOF combo therapy with LDV or DCV to become reimbursable, most centres in Italy have had no better option than prescribing 24 weeks of SOF + RBV as a standard of care for decompensated patients. Another difficult to treat population are cirrhotics infected with genotype 3 and a previous failure to Peg IFN + RBV. While approximately 90% of treatment-naive genotype 3 patients with any degree of disease severity obtained SVR following 24 weeks of SOF + RBV, this same regimen provided suboptimal rates of SVR (62%) in treatment-experienced patients with cirrhosis [19] . While the reasons for treatment refractoriness of the latter group remain elusive, the rates of cure with SOF can only marginally be improved by combination with DCV + RBV (69%) or LDV + RBV (73%) [14] . A higher SVR rate was reported in 12 treatment-experienced cirrhotics receiving 12 weeks of SOF + PegIFN + RBV (83%), yet one must consider in this study the under representation of HCV genotype 1b (the most common in Italy) and the recruitment of patients fit to receive interferon, only. While waiting for availability of a 12-week combination of SOF plus the 2nd generation NS5A inhibitor GS-5816, which in combination with RBV led to the highest response rates in genotype 3 patients (96%) [20] , a widespread policy in Italy is to warehouse genotype 3 patients with minimal fibrosis and treat experienced cirrhotics, since 24 weeks of SOF is reimbursed at a cost similar to the 12-week course of triple therapy.
More reassuring is the therapeutic outlook of genotype 4-infected patients, where, however, an issue is the lack of robust data to demonstrate the superiority of newer combo regimens over the standard of care SOF + RBV, particularly in Egyptian ancestry populations. Indeed, the standard of care of 24 weeks with SOF + RBV provided 100% rates of SVR in a small group of treatment-naïve patients of Egyptian ancestry, a success rate that was slightly attenuated (87%) in treatment-experienced patients of the same descent. Noteworthy, 2nd generation 12-week regimens like LDV + SOF and the BMS TRIO (asunaprevivir + becabluvir + DCV) are of comparably high efficacy in naive patients and predictably of lower cost than SOF and RBV, particularly in treatment experienced patients [21-23, Marcellin P, personal communication]. In the ATU study of SOF, a small group of genotype 4 treatmentexperienced patients with advanced fibrosis of mixed geographical origin (France, Egypt and Middle East) treated with either the standard of care (SOF + RBV) or a combo of SOF plus either SMV or DCV, achieved SVR rates >82% (Table 2b ). While this data needs to be validated in larger studies, there is also a need to explore the effectiveness of these regimens in genotype 4-infected patients with non-d subtypes.
Improving treatment of patients listed for LT and with HCC
The efficacy of all-oral regimens to revert clinical decompensation in interferon-unable hepatitis C patients listed for LT represents a real breakthrough in transplant medicine. In a study of 25 cirrhotic patients with portal hypertension randomized to SOF + RBV for 48 weeks, a majority of patients achieved virological clearance on-therapy (100% in Child Pugh A and 65% in Child Pugh B) with a significant reduction in the rates of clinical events like ascites and encephalopathy, ultimately resulting in an increased chance of delisting [17] . While it is still unknown whether SVR is also associated with a reduction in liver-related mortality in patients who are delisted, in listed patients the prevention of HCV recurrence stands as the real end-point to improve LT outcome, a goal that can be achieved by either pre-LT or post-LT antiviral therapy. Indeed, recurrent hepatitis C is known to have an accelerated course, which may lead to graft or patient death in more than 30% of the cases in the first 5 years post-LT. In a phase 2 study of 61 genotype 1/4 patients awaiting LT who received SOF + RBV until transplant or up to 48 weeks, 92% of patients tested HCV RNA <25 IU/mL at time of transplantation and 29/46 achieved SVR12 (69%). Given that the number of consecutive days with undetectable HCV RNA prior to LT was the strongest predictor of post-transplant cure, the current strategy to prevent post-LT HCV recurrence is to treat the patient as long as needed to achieve 30 days of HCV RNA undetectability pre-LT [24] . Another approach to prevent the life-threatening complications of recurrent HCV is to start antiviral therapy after LT, before graft cirrhosis ensues. A pilot, single arm study assessed the safety and efficacy of SOF and a doseescalating regimen with RBV for 20 weeks in 40 patients with hepatitis C recurrence, including only 12 patients with compensated cirrhosis. SVR12 was achieved in 70% of patients without any significant adverse events or episode of rejection [25] . This was also the outcome of antiviral treatment of severe recurrent HCV within the compassionate use programme with SOF in 104 liver recipients with fibrosing cholestatic hepatitis or decompensated cirrhosis who received therapy up to 48 weeks post-LT. The rates of SVR were 70% in patients with fibrosing cholestatic hepatitis, which is a severe early graft dysfunction due to a direct cytopatic effect of HCV, whereas it was lower (48%) in those with established end-stage cirrhosis. The disadvantage of delayed treatment of recurrent hepatitis C was highlighted by a small compassionate use programme with SOF + DCV in genotype 1 and 4 recipients with severe recurrent hepatitis C who were not eligible to interferonbased therapies [26] and by the registration trial of 12 weeks of SOF + LDV + RBV [27] . In the latter study, the SVR rates were 100% in patients with Metavir F0-4, in 85% of Child Pugh B and 60% of Child Pugh C patients post LT, only. While these data clearly favour treatment of hepatitis C pre-LT to prevent severe complications of recurrent hepatitis C, one obvious question is how to optimize treatment of patients with decompensated liver disease and those who undergo LT earlier than anticipated. In our centre, an option is a bridging SOF + RBV regimen from the pre-LT to the post-LT phase, resulting in a shortened duration of post-LT treatment needed to permanently eradicate the infection [28] . Another reason of concern in the treatment of patients with advanced liver disease is the risk of HCC development, which is not removed in all patients obtaining SVR [29] . In viremic patients with HCC, anti-tumour treatment is often hampered by portal hypertension, which increases the risk of clinical decompensation following hepatic resection or chemoembolization in fragile cirrhotic patients [30] . Reversal or prevention of decompensation and, in general, improvement of Child-Pugh status is a demonstrated benefit of all-oral anti-HCV therapy, and is expected to increase patient access to effective anti-HCC therapy. The benefit of HCV clearance in patients with advanced disease could be even greater in patients with multiple tumour nodules in which local ablation therapy is contraindicated due to the risk of treatment-related clinical decompensation. In the transplantation field, an additional benefit of all-oral therapy is delisting of SVR patients who may receive curative local ablative therapies or hepatic resection, clearly on the assumption that HCV clearance amplifies the applicability of anti-HCC invasive procedures while reducing the risk of liver failure and subsequent primary tumours. Similarly, indication to LT might be expanded in selected SVR patients exceeding Milan criteria, as the increase in the risk of tumour recurrence post-LT may be offset by the prevention of hepatitis C recurrence.
Does SVR improve the outcome of advanced hepatitis C?
Retrospective studies in patients with chronic hepatitis C have independently highlighted a number of clinical benefits of SVR to interferon-based regimens, the most important being a decline in liver-related and all-cause mortality [31] [32] [33] . This was also the conclusion of a recent meta-analysis of 129 studies encompassing 23,309 patients, which, on the other hand, stressed the persistence of the risk of liver transplantation, HCC and death from any cause in several patients achieving SVR to interferon-based regimens (Fig. 1 ) [34] . While the reasons for the residual risk of end-stage liver complications in SVR patients are rather elusive, likely culprits are comorbidities such as diabetes, renal failure and cardiovascular disease that concur in a significant number of HCV-infected patients with HCC and cannot be cured by interferon [33, 35, 36] . One argument against our strategy of restricting all-oral therapy to patients with severe hepatitis only is data correlating the post-SVR risk of HCC with the severity of pre-existing liver disease [29] and, in genotype 1, with the prevalence of genetic mutations in the amino acid 70 and/or 91 of the HCV core region [37] . While the first interpretation favours treatment of patients with early infection rather than those with advanced liver disease, these observations altogether question the cost-benefit of the current life-saving strategies dictated by money constraints, which justify treatment prioritization of patients with more advanced disease. This is also the message of a preliminary report of 120 patients with advanced cirrhosis who were successfully treated with a combination of SOF + SMV for 12 weeks; HCC risk persisted in patients with moderate hepatic dysfunction whereas patients with MELD > 12 did not appear to improve clinically while remaining in need of LT even after achieving SVR (Shiffman et al., personal communication). Overall, previous studies with interferon and preliminary reports of field practice with all-oral DAAs highlight a failure of SVR to provide a universal cure of patients with advanced HCV cirrhosis, whereas they argue against cost-effectiveness of prioritizing patients with advanced fibrosis to DAA therapy.
Renal disease remains a major subgroup needing study
In the interferon era, early treatment of HCV in patients with diabetes was associated with a decline in the rates of end-stage renal disease, myocardial infarction and stroke whereas satisfactory rates of HCV cure were achieved in a subset of patients on chronic haemodialysis [38, 39] . SOF-based regimens are contraindicated in patients with creatinine clearance <30 ml/min owing to the potential toxicity caused by the accumulation of its 007 metabolite cleared by kidney. Currently, in patients with chronic kidney disease the efficacy and safety of such regimens as Viekirax ® + Exviera TM and grazoprevir + elbasvir for genotype 1, SOF + RBV for genotypes 1 and 3 and SMV + DCV for genotypes 1b and 4, are being tested in phase 2 and 3 trials. Less explored is the antiviral treatment of patients with a kidney graft, where patients with HCV genotypes 1 and 4 are being recruited in a phase 2 study with LDV + SOF, only (Table 3) . One major point of interest of studies in renal disease patients is whether successful anti-HCV therapy will favourably impact kidney function, since in some patients renal failure may be accelerated by HCV-related glomerulonephritis.
Surveillance strategies in SVR patients
The reports of a residual risk of HCC in hepatitis C patients obtaining SVR to interferon-based regimens has set the stage for recommending liver cancer surveillance in patients who clear HCV, particularly in those with pre-treatment severe liver disease [30] . This recommendation was clearly validated by a retrospective study in Taiwan of 871 patients with SVR to PegIFN + RBV therapy, where 50 patients developed HCC during a follow-up of 3.5-114 months and an association between risk of developing cancer, patient age and disease severity was reported [29] . The finding that the annual HCC risk was 5% in patients with advanced fibrosis aged >60 years and between 1.8 and 0.3% in those aged <60 years with less severe hepatitis (Fig. 2) provided insights for optimizing ultrasound-based surveillance of SVR patients. Furthermore, this heightens the issues related to cost-benefit of the current therapeutic strategies based on prioritization of DAA therapy in patients with advanced liver fibrosis. Given the rates of all-cause mortality in patients with HCV-related cirrhosis who achieved an SVR, surveillance should also include careful monitoring of extra-hepatic complications. A study in Denmark clearly demonstrated that 24% of HCV patients with cirrhosis had one or more comorbidities related to cardiovascular, neurological, pulmonary or neoplastic disease, accounting for a substantial increase in the mortality compared to cirrhosis patients without comorbidities [35] . In the US, surveillance of SVR patients is strongly recommended in cirrhotics and hepatitis C patients with comorbidities such as overweight, diabetes and chronic alcohol abuse.
The future: how to improve patient access to therapy and prevent reinfection
The skyrocketing, budget-breaking prices of the newer anti-HCV medicines are a real hurdle, which limits patient access to HCV therapy even in resource-rich countries. Due to the strict correlation that exists between pricing of a new drug and the volume of treatments negotiated, a single body negotiation for all European countries might help downsize the cost of newer anti HCV molecules; in the meantime we wait for market competition between companies manufacturing all-oral anti HCV regimens to bring the price of these medicines down to more reasonable levels. The development of even shorter duration regimens (6 weeks) would also enable cost savings, and this can be achieved through a combination of different classes of second generation DAAs. While this strategy stands as a pragmatic approach to deliver less expensive anti-HCV therapy which couples convenience and patient compliance, it also needs to be predictable for different patient populations and must have a real clinical rationale. Preliminary studies indicate that 4-to 8-week regimens can provide optimal rates of SVR, however with the caveat that only non-cirrhotic populations have been tested so far (Table 4) [40] [41] [42] [43] [44] . Along the same line is development of a pangenotypic regimen with all-oral DAAs, with the ultimate goal of removing the barriers represented by the need of sophisticated virological testing. Currently, point of care tests like an oral HCV assay and non-invasive tools to stage liver disease severity, i.e., Fibrotest and Fibroscan, are widely adopted.
Finally, the fact that all currently available therapies failed to induce protective immunity following HCV clearance poses a threat to successful eradication campaigns in geographical areas or communities with high HCV endemicity. Existing data pinpoints the importance of host immunity in association with second wave DAAs in the clearance of HCV. In geographical areas like Japan, Korea and the Far East where the favourable IFN lambda 4 genotype CC predominates among the general population, the SVR rates to SOF and LDV were 100%, whereas in both registration and field practice studies, all HCV1b patients who relapsed to SOF based therapy were non-CC genotype. Notably, the interim report of the C SWIFT trial shows that patients with residual viraemia at the end of a 4-week therapy course become transiently HCV RNA negative at week 2 of post-treatment follow-up without receiving any further antiviral treatment [43] . The clear message of the study that innate immunity matters in achieving HCV eradication in patients exposed to all-oral therapy, matches the need to protect high-risk patients from reinfection with HCV. In fact, therapeutic vaccines based on epitopes of the HCV envelope proteins that are involved in virus neutralization are being investigated in patients who successfully responded to DAAs, for their ability to boost virus-specific immunity.
